Table 6.
Comparison of PSA kinetics between SBRT and CF-EBRT by pre-treatment PSA (probability values)
| |
|
|
Pretreatment PSA (ng/mL) |
|
|---|---|---|---|---|
| ≤10 | >10 | >4 | ||
| |
Through year |
|
|
|
| Nadir PSA (ng/mL) |
|
|
|
|
| |
1 |
ns |
ns |
ns |
| |
2 |
p = 0.001 |
ns |
p = 0.002 |
| |
3 |
p = 0.005 |
ns |
p = 0.001 |
| Time to Nadir PSA (mos.) |
|
|
|
|
| |
1 |
ns |
ns |
ns |
| |
2 |
ns |
ns |
ns |
| |
3 |
p = 0.04 |
p = 0.03 |
p = 0.01 |
| Rate of PSA change: ng/mL/Month |
|
|
|
|
| |
1 |
ns |
ns |
ns |
| |
2 |
p = 0.05 |
ns |
(p = 0.08) |
| 3 | (p = 0.06) | ns | p = 0.02 | |
For each of the 3 pretreatment PSA subsets the PSA outcomes were compared between SBRT and CF-EBRT. The distributions for PSA nadir and PSA slope were compared using the Mann–Whitney test. The distributions for the time to PSA nadir was compared using the log rank test.